Funding Sources

Arbor Research believes that transparency of funding is important to conveying reliable research results, and maintains a diverse base of support for its research activities. In 2018, the organization received 71% of its support directly or indirectly from U.S. government entities, including NIH, HRSA, CMS, and the CDC. The remaining 29% of funding comes from foundations, foreign governmental agencies, and private sponsorships. Since the start of 2018, Arbor Research has received funding from the sources listed below.

Government Agencies

  • Agency for Healthcare Research and Quality (AHRQ)
  • Centers for Disease Control and Prevention (CDC)
  • Center for Medicare & Medicaid Service (CMS)
  • Health Resources and Services Administration (HRSA)
  • National Institutes of Health (NIH)
    • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • U.S. Department of Health and Human Services (HHS)

Private Sector

  • Albireo AB
  • Amgen, Inc.
  • Amgen Limited, Inc.
  • AstraZeneca Pharmaceuticals LP
  • Baxter Healthcare
  • Fresenius Medical Care Asia-Pacific Ltd.
  • Intercept Pharmaceuticals, Inc.
  • Keryx Biopharmaceuticals, Inc.
  • Kyowa Hakko Kirin China Pharmaceutical Co., Ltd.
  • Kyowa Hakko Kirin Co. Ltd (Japan)
  • Vifor Fresenius Medical Care Renal Pharma
  • United HealthCare Services, Inc.

Foundations, Non-profits, and Universities

  • Beth Israel Deaconess Medical Center, Department of Medicine, Division of Nephrology
  • Blue Cross Blue Shield of Michigan Foundation
  • Case Western Reserve University
  • Giannina Gaslini Institute
  • Japanese Society for Peritoneal Dialysis
  • Middlemore Clinical Trials Trust
  • Montefiore Medical Center
  • New York University School of Medicine
  • Patient-Centered Outcomes Research Institute (PCORI)
  • Project Purple
  • The Research Institute at Research Institute Children's Hospital
  • University of Michigan